EGFR tyrosine kinase inhibitors such as gefitinib and erlotinib are approved for first-line treatment of advanced NSCLC in patients with exon 19 deletions and an L858R point mutation in exon 21. This evidence concerns the gene EGFR and non-small cell lung carcinoma.